Pralsetinib
Gavreto · RET inhibitor
Hypertension; rare AKI.
Alunbrig · BRIG
ALK TKI · approved 2017 · 9 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A next-generation ALK inhibitor with usually benign creatinine elevations as its main renal footprint.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
As an ALK inhibitor, brigatinib is associated with creatinine elevations that are generally benign. In a real-world ALK-inhibitor cohort, creatinine-based AKI/CKD events occurred but were mostly mild and reversible across agents including brigatinib; class reviews note elevated creatinine, occasional edema, and rare electrolyte disturbances. A distinct, early-onset pulmonary event (within the first week) is a separate non-renal class concern.Source: Pinard et al., Clin Lung Cancer 2025
Creatinine changes typically emerge within weeks and tend to reverse on discontinuation.
Distilled from: “Creatinine changes typically emerge within weeks and tend to reverse on discontinuation.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Class-level: ~10% AKI by creatinine (KDIGO) within 90d across ALK-TKIs (incl. brigatinib); mostly reversible reduction in tubular creatinine secretion, recovers off-drug
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Drug-specific hypertension in ALK-TKI network meta-analysis, not a class effect.
Tap a signature to trace where it strikes the nephron.
Pseudo-AKI strikes: Proximal Tubule.
Pseudo-AKI
The great mimic — a rise in creatinine from blocked tubular secretion (OCT2/MATE), NOT true injury. The GFR is intact; confirm with cystatin C before stopping effective therapy.
Potent next-generation ALK tyrosine kinase inhibitor with activity against many resistance mutations and CNS disease; also inhibits ROS1 and EGFR variants. Used in ALK-positive non-small-cell lung cancer.
Class-level context for the major non-renal toxicities of the ALK TKI class.
Ophthalmic
Keratopathy, uveitis, retinopathy
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
8 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Quoted verbatim from this agent's current FDA label (Jan 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
Reduce the dose of ALUNBRIG for patients with severe renal impairment. ( 2.7 , 8.7 )
Kidney rows of the label's dosage tables
From the Alunbrig label (Jan 2026) · DailyMed
No row of this label's 2 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 3,655 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
788 of 3,655 reports
Reported with hospitalization
1,004 of 3,655 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Brigatinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Gavreto · RET inhibitor
Hypertension; rare AKI.
Alecensa · ALK TKI
Creatinine rise via reduced tubular secretion.
Zykadia · ALK TKI
GI-driven prerenal AKI.
Lorbrena · ALK TKI
Edema and metabolic effects.
Bosulif · BCR-ABL TKI
Reversible eGFR decline.
Zejula · PARP inhibitor
Hypertension and creatinine rise.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.